Influenza, Human Clinical Trial
Official title:
VRC 309: A Multi-Center, Open-Label, Randomized Phase I Study of an Investigational Influenza DNA Vaccine Followed by 2009/2010 Seasonal Influenza Trivalent Inactivated Vaccine (TIV) Compared to Two Injections of TIV in Adults 45-70 Years
Background:
- Vaccines are substances used to try to create resistance or immunity to a disease and to
prevent an infection. Investigators are looking into improved ways to give and test the
results of different kinds of vaccines.
- Researchers are interested in comparing the results of an experimental DNA vaccine for
the prevention of seasonal influenza against a standard FDA-approved vaccine for the
prevention of seasonal influenza. The experimental DNA vaccine is not yet approved by
the FDA for preventing the flu.
Objectives:
- To test the safety and immune response of an experimental DNA vaccine for seasonal
influenza, compared to the standard vaccine for seasonal influenza.
Eligibility:
- Healthy individuals between ages 45 and 70 who have not yet received the seasonal influenza
vaccine.
Design:
- Participants will have six planned clinic visits (Weeks 0, 1, 3, 4, 6, and 27) and two
telephone follow-up contacts (within 2 days after each injection) during this study.
- Participants will be divided into two groups: one group will receive two standard (TIV)
flu vaccine injections given using a needle and syringe, while the other will receive
the DNA flu vaccine using a needleless injection system followed by the TIV vaccine.
- The vaccine injections for both groups will be given approximately 3 weeks apart,
- Clinic staff will observe participants for at least 30 minutes after each vaccination.
One to two days after each injection, participants must telephone the clinic staff, and
for 7 days after the vaccination participants will keep a diary card to report on
possible side effects.
- During study visits, blood samples will be collected for research purposes to test for
responses to vaccine.
Study Design:
This is a Phase I, open-label study in healthy adults. The study will evaluate the safety,
tolerability, and immunogenicity of a prime-boost vaccination regimen against the seasonal
influenza virus with one dose of an investigational plasmid DNA vaccine as a prime followed 3
weeks later by the seasonal influenza trivalent inactivated vaccine (TIV) boost as compared
to two injections with seasonal TIV. The hypothesis is that the DNA vaccine will be safe for
administration and that the DNA vaccine prime - TIV boost schedule will elicit a greater
frequency and/or magnitude of the antibody response than two injections with the seasonal
TIV. The primary objective is to evaluate the safety and tolerability of the prime boost
vaccine regimens. Secondary and exploratory objectives are related to evaluation of the major
differences in quantity, quality and durability of humoral and cellular immune responses.
Product Description:
The VRC-FLUDNA056-00-VP vaccine was developed and manufactured by VRC, NIAID. It is composed
of 3 closed-circular DNA plasmids, each with a CMV/R promoter, that encode for H1, H3, and
influenza B hemagglutinin (HA) proteins from the same 2009-2010 influenza vaccine strains.
DNA vaccine vials will be supplied at 4 mg/mL with each dose administered in a 1 mL volume.
The TIV is the subunit inactivated vaccine for the 2009-2010 season. Each dose is composed of
45 microg hemagglutinin (HA) in 0.5 mL; with the recommended ratio of 15 microg HA of each of
the following 3 strains: A/Brisbane/59/2007-like (H1N1); A/Brisbane/10/2007-like (H3N2); and
B/Brisbane/60/2008-like. All injections will be administered intramuscularly (IM) in the
deltoid muscle. The DNA injections will be administered by Biojector[Registered Trademark]
2000 Needle-Free Injection Management System and the TIV by needle and syringe.
Subjects:
60 healthy adults, 45-70 years old will be enrolled.
Study Plan:
There are two groups in the study randomized simultaneously at a ratio of 2:1 to the
schedules shown in the schema. All subjects will receive the seasonal influenza TIV vaccine
as the second injection.
The protocol requires 6 clinic visits (Weeks 0, 1, 3, 4, 6, 27) and 2 telephone follow-up
contacts (within 2 days after each injection) for all groups.
;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT03275389 -
A Study to Evaluate the Reactogenicity, Safety and Immunogenicity of GlaxoSmithKline (GSK) Biologicals' Investigational Supra-seasonal Universal Influenza Vaccines - Inactivated (SUIVs) (GSK3816302A) in Healthy Adults Aged 18 to 39 Years
|
Phase 1 | |
| Completed |
NCT03442582 -
Afluria Pregnancy Registry
|
||
| Completed |
NCT05981846 -
A Phase II Trial to Evaluate the Safety and Immunogenicity of BIMERVAX® When Coadministered With Seasonal Influenza Vaccine (SIIV) in Adults Older Than 65 Years of Age Fully Vaccinated Against COVID-19
|
Phase 2 | |
| Completed |
NCT05044195 -
A Clinical Study to Evaluate the Immunogenicity and Safety of an Adjuvanted Quadrivalent Influenza Vaccine Compared With a Licensed Quadrivalent Vaccine in Adults 50 to 64 Years of Age
|
Phase 3 | |
| Completed |
NCT02914275 -
A Study to Evaluate the Immunogenicity and Safety of Seqirus Quadrivalent Influenza Vaccine (QIV) in a Pediatric Population 6 Months Through 59 Months of Age.
|
Phase 3 | |
| Completed |
NCT04590066 -
Testing Multiple Behavioral Science Strategies to Increase Flu-Shot Rates at a Large Retail Pharmacy
|
N/A | |
| Recruiting |
NCT03778203 -
Development of Childhood Anti-influenza Immunity
|
Phase 4 | |
| Completed |
NCT04527614 -
Influence of Prior Infection With COVID-19 on Occurrence of Influenza-like Illness or Acute Respiratory Infection
|
N/A | |
| Terminated |
NCT03658629 -
Phase 2 Dose and Formulation Confirmation of Quad-NIV in Older Adults
|
Phase 2 | |
| Completed |
NCT05269290 -
Efficacy and Safety of Ingavirin®, Syrup, 30 mg/5 ml, in Children With Influenza and Other Acute Respiratory Viral Infections
|
Phase 3 | |
| Completed |
NCT02998996 -
Study to Assess the Safety, Tolerability and Immune Response Following Vaccination With Immunose™ FLU
|
Phase 1/Phase 2 | |
| Withdrawn |
NCT02883972 -
Childhood Influenza Immunisation Invitation Trial in Schools
|
N/A | |
| Completed |
NCT02984280 -
Specific Respiratory Infections as Triggers of Acute Medical Events
|
N/A | |
| Completed |
NCT02867358 -
A Clinical Trial of KT07 Capsule in the U.S.A
|
Phase 2 | |
| Completed |
NCT02545543 -
A Study to Evaluate the Immunogenicity and Safety of Seqirus Quadrivalent Influenza Vaccine (QIV) in a Pediatric Population 5 Through 17 Years of Age
|
Phase 3 | |
| Completed |
NCT02621164 -
Immunogenicity and Safety of Quadrivalent Influenza Vaccine in Children and Adolescents
|
Phase 3 | |
| Completed |
NCT02212106 -
A Study to Evaluate the Safety and Tolerability of Trivalent Influenza Virus Vaccine in Children Aged 5 Years to < 9 Years
|
Phase 4 | |
| Completed |
NCT02243774 -
Mail Outreach To Increase Vaccination Acceptance Through Engagement
|
N/A | |
| Completed |
NCT02344134 -
Study of Egg-derived Influenza Vaccine and Cell Culture-derived Influenza Vaccine in Adult and Elderly Subjects
|
Phase 3 | |
| Completed |
NCT01674205 -
Study of Immune Responses in Healthy Adults Receiving Live Influenza Virus Vaccines
|
Phase 1 |